Last reviewed · How we verify

Huaren Peritoneal Dialysate

Chinese PLA General Hospital · FDA-approved active Small molecule

Huaren Peritoneal Dialysate is a solution used in peritoneal dialysis to remove waste products and excess fluid from the blood through the peritoneal membrane.

Huaren Peritoneal Dialysate is a solution used in peritoneal dialysis to remove waste products and excess fluid from the blood through the peritoneal membrane. Used for End-stage renal disease requiring peritoneal dialysis.

At a glance

Generic nameHuaren Peritoneal Dialysate
SponsorChinese PLA General Hospital
Drug classPeritoneal dialysis solution
ModalitySmall molecule
Therapeutic areaNephrology
PhaseFDA-approved

Mechanism of action

Peritoneal dialysate works by establishing a concentration gradient across the peritoneal membrane, allowing uremic toxins and excess electrolytes to diffuse from the blood into the dialysate solution, which is then drained from the peritoneal cavity. The solution typically contains glucose or other osmotic agents to facilitate ultrafiltration and fluid removal. This process replaces the filtration function of failed kidneys in patients with end-stage renal disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: